ArticleHuman vaccines & immunotherapeutics2020
Hepatitis A vaccination.
Article in Human vaccines & immunotherapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.
- Evolution and Impact of Hepatitis A Epidemiology in Europe-Systematic Literature Review of the Last 20 Years.Journal of viral hepatitis · 2025Pooled it
- Immunogenicity persistence of hepatitis A vaccines Healive® and Havrix® among children:15 years follow-up and long-term prediction.Human vaccines & immunotherapeutics · 2023Trial
- Advances and perspectives in animal models of human hepatitis A virus.Animal models and experimental medicine · 2026Review
- Single-Center Retrospective Study of Hospitalized Hepatitis A Cases in Southern Bulgaria, 2015-2023.Healthcare (Basel, Switzerland) · 2026Article
- Life Course Vaccination Continuum (LCVAC): An Expert Consensus on Life Course Vaccination in India.Cureus · 2026Review
- Seroprevalence of hepatitis A in adolescent students: A cross-sectional study in Curitiba, Paraná, 2024.Epidemiologia e servicos de saude : revista do Sistema Unico de Saude do Brasil · 2026Article
- Coinfection ofCase reports in infectious diseases · 2026Article
- Evolving trends in hepatitis A epidemiology: Shifting patterns, emerging risks, and future strategies.World journal of virology · 2025Review
- Safety Surveillance for Hepatitis A Vaccine using the U.S. Vaccine Adverse Event Reporting System (VAERS) database.Human vaccines & immunotherapeutics · 2025Article
- Immunogenicity and safety in animals of a lyophilized live attenuated hepatitis A vaccine following stabilizer optimization.Scientific reports · 2025Article
- Hepatitis Vaccines: Recent Advances and Challenges.Vaccines · 2025Review
- Current Epidemiological Trends and Public Health Challenges of Hepatitis A Virus Infection in Thailand.The American journal of tropical medicine and hygiene · 2025Review
- Tracking epidemiological shifts in hepatitis A in Portugal: a comparison of seroprevalence between two nationwide surveys, 2001 to 2002 and 2015 to 2016.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025Article
- Regional and age related variations in hepatitis A virus incidence in China 2004 to 2018: a descriptive epidemiological study.Scientific reports · 2025Article
- Rising incidence of acute hepatitis A among adults and clinical characteristics in a tertiary care center of Pakistan.World journal of virology · 2025Article
- Vaccination status and hepatitis A immunity in children: insights from a large-scale study in Turkey.BMC infectious diseases · 2025Article
- Article
- Reverse Vaccinology and Immunoinformatic Approach for Designing a Bivalent Vaccine Candidate Against Hepatitis A and Hepatitis B Viruses.Molecular biotechnology · 2024Article
- Cellular immune response to a single dose of live attenuated hepatitis a virus vaccine in obese children and adolescents.Heliyon · 2024Article
- A Comparative Analysis of Drinking Water Provision and Hepatitis A Incidence in Uzbekistan in 2010-2023.Cureus · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis A is an important public health issue worldwide. Hepatitis A vaccine (HepA) was first licensed in 1992. Both inactivated HepA (HepA-I) and live attenuated HepA (HepA-L) are highly immunogenic and well tolerated, and immune protection postvaccination can persist for at least 20 y. HepA is effective for both preexposure and postexposure prophylaxis, especially among children and young adults. The strategy of HepA vaccination varies in different countries and mainly includes vaccination among high-risk populations, regional childhood vaccination and universal childhood vaccination. The incidence of hepatitis A has decreased greatly in many countries in the last 30 y, but hepatitis A outbreaks frequently occur among high-risk populations and those who have not been covered by universal child vaccination programs in recent years. Disease surveillance and serosurveys are suggested to clarify the shift in the epidemiology of hepatitis A. The long-term persistence of immune protection after one dose of HepA should be further studied, as well as the cost-effective evaluation of different strategies of HepA vaccination. Based on this evidence, the recommendation on HepA vaccination should be put forward scientifically and updated in a timely and well-implemented manner.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.